TRT Clinics Are Selling You Hormonal Chaos

The liver makes IGF-1. That sentence sounds simple, but unpacking what it actually means exposes one of the more expensive mistakes happening in men's health clinics right now.

Here is the full chain so you have the map before we go deeper. Your pituitary gland releases growth hormone, which travels through the bloodstream to your liver, and your liver responds by producing something called IGF-1, which stands for insulin-like growth factor 1 and is the molecule that actually does most of what people attribute to growth hormone itself. Muscle protein synthesis, tissue repair, cellular growth, that is largely IGF-1 doing the work, not growth hormone directly. Growth hormone is the signal. IGF-1 is the action.

Now here is where estrogen enters the picture, and this is the part most people running these protocols do not understand or choose not to explain.

Estrogen is not just a female hormone that men need to suppress. In men, estrogen plays a direct role in how sensitively the liver responds to growth hormone. It does this by upregulating something called growth hormone receptors in the liver, which are the binding sites that allow growth hormone to communicate its instructions. More functional receptors means the liver converts growth hormone into IGF-1 more efficiently. When estrogen drops, receptor expression drops with it, and the same amount of growth hormone circulating in your blood produces less IGF-1.

This is not theoretical. Studies in men with hypogonadism show that estrogen replacement alone, without any change in growth hormone, raises IGF-1 levels. The liver's output changed because the signaling environment changed, not because more growth hormone was provided. That tells you estrogen is not a passive bystander in this system. It is an active regulator of the axis.

So now run through what a standard TRT clinic protocol actually does to this system.

You come in with low testosterone. They prescribe testosterone, which is correct as a starting point. Testosterone aromatizes into estrogen, meaning some of it converts through a process your body runs naturally using an enzyme called aromatase. Your estrogen rises as your testosterone rises, which is exactly what the system is designed to do.

Then your estrogen reading comes back above whatever threshold the clinic uses, and they prescribe anastrozole, which is an aromatase inhibitor, meaning it blocks that conversion and drives estrogen down. Sometimes aggressively.

Your estrogen crashes. And because the liver now has fewer growth hormone receptors to work with, your IGF-1 production falls with it.

Then they measure your IGF-1, find it low, and sell you IGF-1 peptides or injections to replace what they suppressed.

You are paying to create the deficiency and then paying again to correct it.

The reason this matters beyond the money is that injecting IGF-1 exogenously, meaning from outside the body, bypasses the regulation your liver normally applies to this process. Your body produces IGF-1 in response to growth hormone signals and adjusts that production based on your metabolic state, your nutritional status, your sleep, your stress levels. It is a managed output. When you inject IGF-1 directly, you are flooding the system with a fixed dose that does not respond to those signals, and IGF-1 at chronically elevated levels outside of that feedback system is associated with accelerated cellular proliferation, which is not something you want to be running unsupervised for months or years.

The actual medical use case for exogenous IGF-1 is a condition called growth hormone insensitivity syndrome, sometimes called Laron syndrome, where the pituitary produces growth hormone but the liver cannot respond to it at all due to a receptor defect. It affects somewhere around 250 to 500 people in the entire world at any given time. That is the population this therapy was designed for. The idea that it is now being offered as a routine add-on at TRT clinics to men whose primary issue is suppressed estrogen from overuse of anastrozole is a meaningful departure from the clinical rationale for the drug.

The simpler answer, almost always, is to stop suppressing estrogen so aggressively.

Men on TRT who maintain estrogen in a healthy physiological range, roughly 20 to 30 picograms per milliliter based on most endocrinology guidelines, tend to have IGF-1 levels that reflect their testosterone levels appropriately without any additional intervention. The system works when you let it work. The problem is that anastrozole is cheap to prescribe, easy to justify on a lab report, and does not require the kind of nuanced management that titrating testosterone dose to control estrogen conversion actually takes.

There is also an asymmetry in how these clinics handle the problem. If your estrogen is somewhat elevated but you have no symptoms of high estrogen, that is a conversation about whether intervention is needed at all. If your estrogen is crashed and you have low libido, joint pain, fatigue, and poor mood, that is a medical problem that needs to be corrected. But correcting it with IGF-1 rather than by adjusting the anastrozole dose is like fixing a leaking faucet by building a drainage system for the floor.

What you actually want to know before spending anything on peptides is whether your estrogen has been suppressed below the normal range, because if it has, no amount of growth hormone support is going to work the way you think it will. A single lab test tells you this. If your estradiol is below 20 picograms per milliliter and your IGF-1 is low, the low IGF-1 is probably a consequence, not a primary problem, and the solution is upstream.

The real cost here is not just financial. It is that when men go through multiple interventions simultaneously, adding testosterone, then anastrozole, then IGF-1, then possibly an AI adjustment, then possibly a peptide to address a symptom from the previous intervention, you lose the ability to know what is actually working. The system becomes unreadable. You cannot tell what caused what, and every new symptom generates a new prescription rather than a reason to simplify.

Hormonal optimization done correctly is a process of getting one axis working properly and then observing what the rest of the system does. Most of the time, the rest of the system corrects itself, because these pathways are connected and they are trying to reach equilibrium. The clinic model that sells you five interventions at once is not optimizing your hormones. It is managing the side effects of its own protocol, and charging you for the privilege at each step.

That is the business model.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness